Eli Lilly’s (LLY) diabetes treatment, Mounjaro, has surged to become the world’s top-selling drug, generating $8.66 billion in first-quarter sales—more than double the revenue from a year ago. This impressive growth has propelled Lilly’s overall revenue to $19.79 billion, a 56% increase, with net income skyrocketing 168% to $7.39 billion. The drug’s success is bolstered by its recent inclusion in China’s National Reimbursement Drug List, expanding its international market reach.
This performance not only eclipses Merck’s Keytruda, which generated $7.9 billion, but also positions Lilly as a dominant player in the diabetes and anti-obesity sectors. The company’s portfolio, which includes the weight-loss drug Zepbound and the newly launched Foundayo, is expected to drive revenues higher, with projections reaching $84.4 billion this year and nearly $100 billion by 2027.
For investors, Lilly’s robust growth trajectory and expanding product offerings make it a compelling stock to consider, especially as the demand for obesity treatments continues to rise globally.
Source: fool.com